🧾 What This Document Is

This is a definitive proxy statement (DEF 14A) for InfuSystem Holdings. Think of it as an invitation and information packet for the company's annual shareholder meeting. Its main jobs are to:

Announce the virtual Annual Meeting on May 11, 2026.
Explain the issues shareholders will vote on (called "proposals").
Provide detailed background information so shareholders can make informed decisions.

👉 It's not about one big event, but about the ongoing governance and direction of the company.

🏢 What The Company Does

In simple terms, InfuSystem is a healthcare services platform that helps doctors and hospitals manage medical devices and treatments for patients outside of a traditional hospital setting.

👉 Their business model: They sit in the middle of a three-way relationship:

For Healthcare Providers: They handle the logistics, delivery, and maintenance of complex medical equipment (like infusion pumps for chemotherapy or devices for wound care).
For Patients: They provide support and manage therapy at home, improving the patient experience.
For Insurance Companies (Payors): They manage billing and reimbursement, helping to lower overall costs.

This lets hospitals extend care into the home, which is a growing trend in healthcare.

💰 Financial Highlights & Performance

Fiscal 2025 was a very strong year for InfuSystem, with record results and improved profitability.

Record Revenue: $143.4 million (up 6% from 2024).
Soaring Profit: Net income jumped 183% to $6.6 million.
Key Metric (Adjusted EBITDA): Grew 24% to a record $31.5 million. The margin expanded by over 300 basis points to 21.9%.
Cash Generation: Operating cash flow hit a record $24.4 million (up 19%).
Balance Sheet Health: They paid down debt significantly, reducing net debt by 30% to $16.4 million. Their leverage ratio is a very low 0.52 times their Adjusted EBITDA.
Returning Cash: They bought back $9.9 million of their own shares, retiring 1.3 million shares.

👉 The big story: InfuSystem is growing its sales and becoming much more efficient, leading to more profit and cash for the company.

🚀 Key Strategic Moves

The company is actively diversifying beyond its core oncology (cancer care) business.

Wound Care Explosion: This new segment grew over 160% in Q4 2025, driven by a partnership with Smith+Nephew and a new device launch.
Strategic Acquisition: They bought Apollo Medical Supply to get a better revenue cycle management platform, which reduces costs and increases capacity.
Smart Investments: They spent about $3.3 million on a major technology upgrade. This is expected to finish in Q1 2026, after which they'll start seeing productivity gains.
Profitability Focus: A tough but necessary decision was made to restructure their largest biomedical services contract. This will reduce 2026 revenue by $7.1 million but is expected to increase earnings and cash flow because the cost savings are even larger.

👉 They are deliberately trading some top-line revenue for better-quality, more profitable revenue.

📦 Board & Governance

Shareholders will vote to elect seven directors. The board includes a mix of expertise:

Carrie Lachance (49): The new CEO, promoted in May 2025 after 15+ years at the company.
Ronald Hundzinski (67): The new Chairman, a former CFO with deep finance experience.
Dr. Kenneth Eichenbaum (49): A practicing anesthesiologist, bringing a direct clinical perspective.
Beverly Huss (66): A former CEO with extensive medical device industry experience.
Scott Shuda (60) & Dr. John Sviokla (68): Bring investment, strategy, and AI/digital expertise.

👉 The board has been refreshed with new leaders and specialized skills to guide the company's next phase.

📊 Proposal Breakdown: What You're Voting On

Here are the four main items on the ballot:

Election of Directors: Vote for all seven nominees listed above.
"Say-on-Pay" (Advisory Vote): An advisory, non-binding vote to approve executive compensation. This lets shareholders voice their opinion on how top executives are paid.
Increase the Equity Plan: Approve adding 1,000,000 more shares to the company's incentive plan. This pool is used to grant stock options and awards to attract and retain talent. As of March 20, 2026, only about 237,300 shares were left in the plan.
Ratify the Auditor: Re-appoint Grant Thornton LLP as the independent accounting firm for 2026.

👉 The Board recommends voting "FOR" all four proposals.

🔮 What's Next

Looking ahead to 2026, management has provided a forecast.

Revenue Guidance: After adjusting for the contract restructuring, they project 6% to 8% pro-forma revenue growth.
Margin Guidance: Adjusted EBITDA margins are expected to continue in the mid to low 20% range.
Focus: They will continue expanding into new therapy areas (like wound care and other home medical equipment), leveraging their existing payor network and infrastructure.

👉 The strategy is disciplined growth: expanding the platform while staying focused on profitability, not just revenue size.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Scaled Platform: A massive, hard-to-replicate network with ~840 insurance contracts covering over 96% of the U.S. population.
Capital Efficiency: They can add new therapies (like wound care) with minimal extra investment because they use their existing infrastructure.
Strong Balance Sheet: Low debt and high liquidity provide flexibility to invest or return capital.
Clear Strategic Direction: Focused on diversification and profitable growth under new leadership.

⚠️ Risks:

Concentration Risk: Oncology remains their largest business segment.
Execution Risk: Success depends on continuing to launch new therapies and integrate acquisitions smoothly.
Regulatory & Reimbursement: As a healthcare services company, changes in insurance rules or reimbursement rates could impact the business.

🧠 The Analogy

InfuSystem is like the "FedEx for Complex Home Healthcare." They don't own the hospitals (the factories) or the drugs (the packages). Instead, they've built a specialized logistics and customer service network that delivers the equipment, manages the treatment schedule at the patient's home, and handles all the complicated paperwork with the insurance company. Their strength is in this connected system, and they're now using that same system to deliver new types of "packages" (like wound care devices) beyond their original specialty.

🧩 Final Takeaway

InfuSystem had a stellar 2025, proving its ability to grow profitably. This proxy meeting is about solidifying the leadership team and the tools (like the equity plan) needed to execute a clear strategy: using its efficient, scaled platform to expand into new home-based medical services while maintaining financial discipline.

InfuSystem Holdings, Inc — DEF 14A Filing